Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714555 · ClinicalTrials.gov registry record · Phase 2
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03714555 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 1 participants.
The verdict
NCT03714555, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.
Interventions
- DIAGNOSTIC_TEST Tumor Imaging
- OTHER Physical Exam
- DIAGNOSTIC_TEST Safety Laboratories
- OTHER AE Assessment
- OTHER Concomitant Medication Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2020-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03714555
The ClinicalTrials.gov registry entry for NCT03714555 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tumor Imaging is the first listed.
NCT03714555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03714555 about?
NCT03714555 is a clinical study titled "Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine". This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a ...
What is the current status of trial NCT03714555?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-17. Estimated completion is 2020-07-29.
What interventions are being tested in trial NCT03714555?
The interventions under investigation include: Tumor Imaging (DIAGNOSTIC_TEST), Physical Exam (OTHER), Safety Laboratories (DIAGNOSTIC_TEST), AE Assessment (OTHER), Concomitant Medication Review (OTHER).
Who is sponsoring clinical trial NCT03714555?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.